GEA
BMY.RT

Glen Eagle Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Glen Eagle Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-800
Closed -$552 – 1035
2020
Q4 		$552 Sell
800
-1,600
-67% -$3.41K ﹤0.01% 939
2020
Q3 		$5.4K Hold
2,400
– – ﹤0.01% 685
2020
Q2 		$8.59K Sell
2,400
-1,600
-40% -$5.77K ﹤0.01% 589
2020
Q1 		$15.2K Buy
4,000
+3,200
+400% +$10.5K 0.01% 449
2019
Q4 		$2.41K Buy
+800
New +$2.08K ﹤0.01% 768

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Glen Eagle Advisors's BMY.RT Position: Q1 2021 in Review

Glen Eagle Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 800 shares — an estimated $552 sold.

Glen Eagle Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $15.2K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Glen Eagle Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 800 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $552.
  • Glen Eagle Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Glen Eagle Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $15.2K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Glen Eagle Advisors's 13F filing for Q1 2021, filed 13 Aug 2024.